@zach_wallace_md on RTX vs CYC remission induction in AAV. Multivariable and propensity score matching. No difference in ESRD or mortality. Real world confirmation of RAVE. Abstr#954 #ACR21 @RheumNow https://t.co/oSauqV8JnD

Does AAV induction choice (CYC v RTX) affect long-term outcomes (that might be missed in clinical trials)? Boston data done two ways: multivar analysis & trial emulation using PS CYC and RTX-based induction both perform equally well over many years👍 #ACR21 ABST0954 @RheumNow https://t.co/8BZRgKiQNB

Dr Strand presents HRQoL measures for avacopan from ADVOCATE trial. Better HRQoL outcomes with avacopan. Great to have PRO data. Abstr#0955 #ACR21 @RheumNow https://t.co/9qBAHETX7s

@SattuiSEMD presents @rheum_covid data on COVID-19 outcomes in vasculitis/PMR. High rates of severe outcomes, particularly for AAV and GCA (mortality >20% for both). Multiple factors associated with outcomes (see below). Abstr#952 #ACR21 @RheumNow #ACRBest https://t.co/0lw1QhuJct

So important for our systemic vasculitis & PMR pts, @rheum_covid data highlighting the outsized COVID-19 risks they face. Thanks @SattuiSEMD @RichardPAConway @EBRheum in particular for driving forward this badly needed work! #ACR21 ABST0952 @RheumNow https://t.co/L7XS9OblxI https://t.co/LYxR1WUlhM

• David Liew on Twitter: "Looking forward to hearing it presented by @Sattui…

#ACR21 #Abstr0437 OK, so RTX affects #COVID vaccine but some pts need RTX. Factors predicting response to vaccine: RA vs AAV/IIM Higher IgG Longer time-to-RTX Lower RTX courses Number. Prediction Calculator is developed but need ext. validation #RheumNow https://t.co/iXSaGQ76hS https://t.co/WQAV3GRPBz

• You searched for - ACR Meeting Abstracts

Dr. Marvisi presented a case: refractory MPA relapsed w/prednisone < 25 mg/day. Genetic studies c/w VEXAS. Is MPA/vasculitis part of VEXAS? The experts say: Maybe- VEXAS is such a new entity, there may be a common pathway (e.g NFkB affected by ubiquination, IL-6 role) #ACR21 https://t.co/kEOsruJ8DE